Photys Therapeutics Stock

photys.comHealthcareFounded: 2022

Photys Therapeutics is a biopharma company that uses its proprietary bifunctional small molecules platform to unlock fine-tuned control of protein function, repair signaling to amplify endogenous disease-fighting mechanisms. Photys was founded by the Broad Institute's leading bifunctional chemist, Amit Choudhary, and the Longwood Fund, alongside a scientific advisory board comprised of distinguished scientists and drug developers.

Register for Details

For more details on financing and valuation for Photys Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Photys Therapeutics.

Register Today

Photys Therapeutics investors also invested in these private companies


Management Team

Brian Fenton
President & Chief Executive Officer
Edward Holson, PhD
Chief Science Officer & Co-Founder
Jeff Capello
Interim Chief Financial Officer

Board Members

Lizzie Ngo
Longwood Fund
David Steinberg
Luke Evnin
MPM Capital
Otello Stampacchia
Omega Funds
Briggs Morrison
Syndax Pharmaceuticals
Alon Lazarus
Investment Partner

Other companies like Photys Therapeutics in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


Photys Therapeutics has debuted with a $75 million Series A funding round. The startup focuses on phosphorylation-inducing chimeric small molecules (PHICS) — a new class of bifunctional medicines that can direct and repair protein phosphorylation.